BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20260925T132850EDT-3265HK2xBb@132.216.98.100
DTSTAMP:20260925T172850Z
DESCRIPTION:Low Molecular Weight Heparin and Cancer Mortality: Too Good to 
 be True?\n\nSpeaker: Marc Carrier\, MD\, MSc\, FRCPC\n\nHead of the Divisi
 on of Hematology\, The Ottawa Hospital\n	Professor\, Faculty of Medicine\, 
 Department of Medicine\n	Senior Scientist in Clinical Epidemiology Program
 \n	The Ottawa Hospital Research Institute\n\nEducational Objectives: \n\n\n
 	To understand the mechanisms linking hypercoagulability and metastatic dis
 ease following cancer surgery\n	To briefly discuss potential antimetastatic
  properties of low molecular weight heparin (LMWH)\n	To review the results 
 of the PERIOP-01 trial assessing the role of extended duration thromboprop
 hylaxis with LMWH in patients undergoing localized colorectal cancer resec
 tion\n\n\n\n	\n\nJoin the Medical Grand Rounds on Microsoft Teams meeting.
 \n	Or call in (audio only) NEW: +1 438-799-0762\, 502095193# Canada\, Montr
 eal\, Phone Conference ID: 502 095 193#\n\nThe Medical Grand Rounds are an
  accredited group learning activity as defined by the Maintenance of Certi
 fication Program of the Royal College of Physicians and Surgeons of Canada
 .\n\nSome Rounds were video recorded.\n\nFull JGH Medical Grand Rounds Sch
 edule\n
DTSTART:20230320T163000Z
DTEND:20230320T173000Z
SUMMARY:Low Molecular Weight Heparin and Cancer Mortality: Too Good to be T
 rue?
URL:https://www.mcgill.ca/deptmedicine/channels/event/low-molecular-weight-
 heparin-and-cancer-mortality-too-good-be-true-346594
END:VEVENT
END:VCALENDAR